Author Interviews, Connective Tissue Disease / 17.05.2014
SLE: BAFF Antagonist For Treatment of Severely Active Disease
MedicalResearch.com Interview with:
Dr Renee Martin
Anthera Pharmaceuticals, Inc.
25801 Industrial Blvd, Suite B.,
Hayward, CA 94545,
MedicalResearch: What are the main findings of the study?
Dr. Martin: The PEARL-SC study identified many key elements that inform the further development of blisibimod for treatment of SLE:
i. That patients with severely active disease responded well to blisibimod,
ii. That a dose of 200mg blisibimod administered subcutaneously once per week improved measures of SLE disease activity,
iii. That greater treatment effect was observed when the SRI-7 and SRI-8 endpoints were evaluated, presumably because the criteria for these endpoints (including 7- or 8- point improvements in SELENA-SLEDAI score, respectively, along with no new BILAG A or 2B scores, and no worsening of physician’s global assessment score) demand substantial improvement in disease activity compared with baseline, and are unlikely to be met by chance (e.g. in the placebo group), and
iv. That blisibimod was safe and well-tolerated over 24-52 weeks of continuous therapy.
(more…)